Recent news on Ziconotide

Ziconotide Syrup (Ziconotide capsule) Information  -  May 17, 2007
American Chronicle,Ziconotide medication belong to Analgesic class. Ziconotide undetermined; however, animal data indicate that ziconotide blocks N-type calcium channels by

Nurture local scientists for economic growth  -  May 6, 2007
ABS CBN News,Filipino scientists Dr. Baldomero Olivera and Dr. Lourdes Cruz were the first to study prialt ziconotide, a pain killer 1000 times more powerful than

Ireland's Elan still smiling despite increase in losses  -  Apr 25, 2007
Pharma Times (subscription),...for the severe pain treatment Prialt (ziconotide), while in the first quarter of 2007, it took a $18.8 million charge on the early retirement of debt.

Harnessing the therapeutic power of venom  -  Apr 12, 2007
BiopharmaReporter.com,It developed Prialt (ziconotide), a non-opioid pain killer that blocks N-type calcium channels. The drug is a synthetic version of a peptide found in cone

Consensus Panel Issues New Guidelines For Pain Management Via  -  Mar 15, 2007
Pharmaceutical Online (press release),The new algorithm includes ziconotide (PRIALT, Elan Corp.) as an alternative to first-line opioids, morphine and hydromorphone and as a second-line

Tysabri forecast to drive Elan's return to profitability  -  Feb 21, 2007
Pharma Times (subscription),Severe pain treatment Prialt (ziconotide) brought in $3.4 million, up 70%, but the main growth drivers were Elan's manufacturing revenue and royalties,

Polyanalgesic Consensus Panel Issues New Guidelines for Pain ...  -  Feb 8, 2007
American Digital Networks (press release),The new algorithm includes ziconotide (PRIALT, Elan Corp.) as an alternative to first-line opioids, morphine and hydromorphone and as a second-line

RMTC Submits Anabolic Steroid Model Rule for Approval  -  Feb 22, 2007
TheHorse.com,...pulmonary hemorrhage) by Dr. Eric Birks; and Detection of the cone snail toxin ziconotide in equine serum by Dr. Rick Sams of the University of Florida.

Eisai Starts Marketing Severe Chronic Pain Agent Prialt in the UK ...  Jul 31, 2006
...of Tokyo (President and CEO: Haruo Naito) started marketing non-opioid severe chronic pain agent Prialt (generic name: ziconotide acetate) in the UK and Gemany ... -PharmaLive.com

Elan says losses narrow in Q2  Aug 1, 2006
Severe pain treatment Prialt (ziconotide) brought in $3 million, up from $1.8 million in the second quarter of 2005 when it was launch in the USA. ... -Pharma Times (subscription)

The deadly sea snail venom that will take away your pain  Jul 9, 2006
Prialt, or ziconotide, is the result of more than 20 years’ research by a scientist born in the Philippines, Baldomera Olivera, who is a professor at the ... -Times Online

Painkiller Based on Sea Snail Venom Made Available in Britain  Jul 11, 2006
The drug Prialt, or ziconotide, has resulted from over 20 years' of research by the scientist, Baldomera Olivera, a professor at the University of Utah. ... -MedIndia



Pain Therapeutics - Drugs, Markets and Companies  17 May 2006
Cone shells contain therapeutically useful peptides including the conotoxins, and one such peptide, ziconotide, has been approved. ... - PharmaLive.com

Neuropathic Pain: An Update on Effective Management Strategies  May 5, 2006
...central sensitization by affecting calcium channels include gabapentin, pregabalin, levetiracetam, oxcarbazepine, lamotrigine, topiramate, and ziconotide. ... - Medscape (subscription)





Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
Elan Corporation, plc today announced that it hascompleted the sale of the rights to Prialt(TM) (ziconotide, non-opioidsevere chronic pain agent) in Europe to ... - Finanzen.net

Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt(TM) (ziconotide, non-opioid severe chronic pain agent) in Europe ... - Genetic Engineering News

Elan closes sale of rights to Prialt In Europe to Eisai  Mar 21, 2006
Irish drugs firm Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt (ziconotide, non-opioid severe chronic pain agent ... - FinFacts Ireland

Elan Closes Sale of Rights to Prialt In Europe to Eisai  Mar 20, 2006
BUSINESS WIRE)--March 20, 2006--Elan Corporation, plc today announced that it has completed the sale of the rights to Prialt(TM) (ziconotide, non-opioid severe ... - Business Wire



Elan to Sell Rights to Prialt in Europe to Eisai  Feb 8, 2006
9, 2006--Elan Corporation, plc today announced that it has agreed to sell the rights to Prialt(TM) (ziconotide, non-opioid severe chronic pain agent) in Europe ... - Business Wire,

Elan to Sell Rights to Prialt in Europe to Eisai  Feb 8, 2006
Elan Corporation, plc today announced that it has agreedto sell the rights to Prialt(TM) (ziconotide, non-opioid severechronic pain agent) in Europe to Eisai Co ... - Finanzen.net,

Eisai Acquires European Rights to Prialt, Severe Chronic Pain ...  Feb 10, 2006
9 the conclusion of an agreement for Eisai's strategic product acquisition in Europe of Elan's non-opioid severe chronic pain agent Prialt (ziconotide acetate ... - Japan Corporate News,

Elan Sells European Prialt Rights To Eisai For $100M  Feb 9, 2006
Prialt (ziconotide) has orphan drug status in the European Union, where it will treat severe, chronic pain in patients who require intrathecal analgesia. ... - BioWorld Online (subscription),

Gokongweis had GSIS for lunch  Jan 12, 2006
Baldomero Olivera and Lourdes Cruz of ziconotide, a non-addictive painkiller developed from soil bacteria that is said to be a thousand times more powerful ... - INQ7.net

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional